Objectiv To investigate the effect of Batroxobin in the treatment of sudden deafness with full frequency decline and its correlation with batroxobin sensitivity and coagulation function. Method A retrospective analysis of 48 cases of sudden deafness with full frequency decline from January 2019 to February 2021 in our hospital was conducted. According to the changes of fibrinogen, the patients were divided into sensitive group and non sensitive group. The coagulation function of the patients was detected, including the changes of activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT) and fibrinogen (FIB), and the changes of pure tone hearing threshold before and after treatment. Results (1) The total effective rate of non batroxobin sensitive group was lower than that of batroxobin sensitive group (P = 0.043). After 10-14 days of treatment, there was no significant difference in absolute value of hearing threshold improvement between batroxobin sensitive group and non sensitive group (P = 0.28) (2) FIB and APTT decreased (P < 0.05), TT and Pt increased (P < 0.05) in 48 patients before and after treatment. (3) There was no significant difference in coagulation function (FIB, TT, APTT, PT) between batroxobin sensitive group and non sensitive group before treatment (P > 0.05); FIB of the two groups decreased after treatment (P < 0.05), And the sensitive group was lower than the non sensitive group (P < 0.05), TT was increased (P < 0.05), and the sensitive group was higher than the non sensitive group; the PT of the sensitive group was higher than that before treatment (P < 0.05), APTT was lower than that before treatment (P < 0.05); the APTT and Pt of the non sensitive group had no significant difference compared with that before treatment (P > 0.05); the PT of the sensitive group was higher than that of the non sensitive group after treatment (P < 0.05), APTT had no significant difference righteousness Conclusion Batroxobin sensitivity is closely related to clinical treatment effect, which is closely related to fib, Pt and TT, and is not related to APTT. However, the body may reduce the risk of bleeding through the endogenous coagulation function of APTT. Batroxobin can enhance anticoagulant function, promote inner ear microcirculation, and reduce risk by keeping anticoagulation, fibrinolysis and coagulation in a certain balance.